Showing results 2 to 2 of 2
< previous
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
Phase 3, randomized, double-blind, dummy-controlled, trial of radiofrequency ablation (RFA) + lyso-thermosensitive liposomal doxorubicin (LTLD, Thermodox), for hepatocellular carcinoma (HCC) lesions 3-7 cm Proceeding/Conference:Annual Conference of the International Liver Cancer Association, ILCA 2013 | - | 53 |